Skip Nav Destination
Issues
1 January 2021
-
Cover Image
Cover Image
The extracellular matrix (ECM) is known to both interact with tumor and stromal cells and mediate their interactions with one another, with significant implications for disease progression and response to therapy. The cover depicts multicolor immunofluorescence of MCF7 breast cancer cells cultured inside a fibroblast-derived, decellularized ECM scaffold. The scaffold contains fibrillar ECM proteins including collagen I (green) and fibronectin (red). Cancer cells were stained with DAPI (DNA – blue) and Phalloidin (F-actin – cyan). Using this model, the authors demonstrated that breast cancer cells receive cues from both the ECM fibers and other bound growth factors with significant implications for estrogen receptor activity and response to antiestrogens. For more information, see the Highlight on page 1 and the article on page 136. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1541-7786
EISSN 1557-3125
Journal Archive
Molecular Cancer Research (2002-Present; volumes 1-current)
(ISSN 0008-5472) Published monthly since November, 2002.Cell Growth & Differentiation (1990-2002; volumes 1-13)
(ISSN 1044-9523) Published monthly 1990- September, 2002.Table of Contents
Highlights
Reviews
Perspective
Rapid Impact
Cancer Genes and Networks
Author Choice
A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma
Tiantian Cui; Erica H. Bell; Joseph McElroy; Kevin Liu; Ebin Sebastian; Benjamin Johnson; Pooja Manchanda Gulati; Aline Paixao Becker; Ashley Gray; Marjolein Geurts; Depika Subedi; Linlin Yang; Jessica L. Fleming; Wei Meng; Jill S. Barnholtz-Sloan; Monica Venere; Qi-En Wang; Pierre A. Robe; S. Jaharul Haque; Arnab Chakravarti
Cell Fate Decisions
Genome Maintenance
Metabolism
Signal Transduction and Functional Imaging
Tumor Microenvironment and Immunobiology
Acknowledgment to Reviewers
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.